Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs
Tóm tắt
Từ khóa
Tài liệu tham khảo
Dine, 2017, Immune checkpoint inhibitors: an innovation in immunotherapy for the treatment and management of patients with cancer., Asia Pac J Oncol Nurs, 4, 127, 10.4103/apjon.apjon_4_17
Webster, 2014, The immune checkpoint inhibitors: where are we now?, Nat Rev Drug Discov, 13, 883, 10.1038/nrd4476
Fukumura, 2018, Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges., Nat Rev Clin Oncol, 15, 325, 10.1038/nrclinonc.2018.29
Fridman, 2017, The immune contexture in cancer prognosis and treatment., Nat Rev Clin Oncol, 14, 717, 10.1038/nrclinonc.2017.101
Blumenthal, 2017, Milestone analyses of immune checkpoint inhibitors, targeted therapy, and conventional therapy in metastatic non-small cell lung cancer trials: a meta-analysis., JAMA Oncol, 3, e171029, 10.1001/jamaoncol.2017.1029
The Lancet Oncology, 2018, Immunotherapy: hype and hope [editorial]., Lancet Oncol, 19, 845, 10.1016/S1470-2045(18)30317-6
The Lancet Oncology, 2017, Calling time on the immunotherapy gold rush [editorial]., Lancet Oncol, 18, 981, 10.1016/S1470-2045(17)30521-1
O’Connor, 2018, Speed of adoption of immune checkpoint inhibitors of programmed cell death 1 protein and comparison of patient ages in clinical practice vs pivotal clinical trials., JAMA Oncol, 4, e180798, 10.1001/jamaoncol.2018.0798
Marquart, 2018, Estimation of the percentage of US patients with cancer who benefit from genome-driven oncology., JAMA Oncol, 4, 1093, 10.1001/jamaoncol.2018.1660
Dietel, 2018, 130O Real-world prevalence of PD-L1 expression in locally advanced or metastatic non-small cell lung cancer (NSCLC): the global, multicentre EXPRESS study., J Thorac Oncol, 13, S74, 10.1016/S1556-0864(18)30404-0
Aggarwal, 2016, Prevalence of PD-L1 expression in patients with non-small cell lung cancer screened for enrollment in KEYNOTE-001,-010, and-024., Ann Oncol, 27, 10.1093/annonc/mdw378.14
Balar, 2017, First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study., Lancet Oncol, 18, 1483, 10.1016/S1470-2045(17)30616-2
Remon, 2018, Immune checkpoint inhibitors in non-small cell lung cancer (NSCLC): approaches on special subgroups and unresolved burning questions., Cancer Treat Rev, 64, 21, 10.1016/j.ctrv.2018.02.002
Khozin, Real-world outcomes of patients with metastatic non-small cell lung cancer treated with programmed cell death protein 1 inhibitors in the year following US regulatory approval, Oncologist
Hsu, 2018, Effectiveness and safety of immune checkpoint inhibitors: a retrospective study in Taiwan., PLoS One, 13, e0202725, 10.1371/journal.pone.0202725
De Souza, 2017, Off-label immunotherapy prescription: financial implications for payers and patients., J Clin Oncol, 35, 6, 10.1200/JCO.2017.35.8_suppl.6
2018
Kolata
Rodriguez FernandezC. Are PD-1 and PD-L1 checkpoint inhibitors as good as we thought? https://labiotech.eu/features/pd-1-pd-l1-checkpoint-inhibitors/. Published September 4, 2018. Accessed October 12, 2018.
US Food and Drug Administration. Drugs@FDA: FDA approved drug products. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm. Accessed June 20, 2018.
American Cancer Society. Understanding your diagnosis: cancer staging. https://www.cancer.org/treatment/understanding-your-diagnosis/staging.html. Accessed June 27, 2018.
Healio Immuno-Oncology Resource Center. Phase 3 trial of pembrolizumab for advanced HCC fails to meet primary endpoints. https://www.healio.com/hematology-oncology/gastrointestinal-cancer/news/online/%7Ba1a112d0-3f4c-425b-bb25-0823c56e56e6%7D/phase-3-trial-of-pembrolizumab-for-advanced-hcc-fails-to-meet-primary-endpoints. Accessed February 27, 2019.
US Government Accountability Office. New drug approval: FDA needs to enhance its oversight of drugs approved on the basis of surrogate endpoints. https://www.gao.gov/products/GAO-09-866. Accessed February 27, 2009.